WesleyInman
Well-known member
Whats up guys.
Check out this new Beta Version of GW-501516
And when I say "Beta" this simply means the labels that are on this are generic, and dont' represent the final labels.
The product is 10mgs per capsule. A bottle has 60 capsules.
Lab Tested High quality GW!!
Use code "WES20" at checkout for 20% off this and all the other fine products at
Invalid Link Removed
GW-501516 is a selective agonist (activator) of the PPARδ receptor which regulates fat burning through a number of widespread mechanisms; it increases glucose uptake in skeletal muscle tissue and increases muscle gene expression, especially genes involved in preferential lipid utilization. This shift changes the body’s metabolism to favor burning fat for energy instead of carbohydrates or muscle protein, potentially allowing clinical application for obese patients to lose fat effectively without experiencing muscle catabolism or the effects and satiety issues associated with low blood sugar.
GW-501516 also increases muscle mass, which improved glucose tolerance and reduced fat mass accumulation even in mice fed a very high fat diet, suggesting that GW-501516 may have a protective effect against obesity. Furthermore in rats treated with GW-501516, increased fatty acid metabolism in skeletal muscle and protection against diet-induced obesity and type II diabetes was observed. In obese rhesus monkeys, GW-501516 increased high-density lipoprotein (HDL) and lowered very-low-density lipoprotein (VLDL). The mechanism by which PPARδ agonists increase HDL appears to be a result of increased expression of the cholesterol transporter ABCA1.
Check out this new Beta Version of GW-501516
And when I say "Beta" this simply means the labels that are on this are generic, and dont' represent the final labels.
The product is 10mgs per capsule. A bottle has 60 capsules.
Lab Tested High quality GW!!
Use code "WES20" at checkout for 20% off this and all the other fine products at
Invalid Link Removed
GW-501516 is a selective agonist (activator) of the PPARδ receptor which regulates fat burning through a number of widespread mechanisms; it increases glucose uptake in skeletal muscle tissue and increases muscle gene expression, especially genes involved in preferential lipid utilization. This shift changes the body’s metabolism to favor burning fat for energy instead of carbohydrates or muscle protein, potentially allowing clinical application for obese patients to lose fat effectively without experiencing muscle catabolism or the effects and satiety issues associated with low blood sugar.
GW-501516 also increases muscle mass, which improved glucose tolerance and reduced fat mass accumulation even in mice fed a very high fat diet, suggesting that GW-501516 may have a protective effect against obesity. Furthermore in rats treated with GW-501516, increased fatty acid metabolism in skeletal muscle and protection against diet-induced obesity and type II diabetes was observed. In obese rhesus monkeys, GW-501516 increased high-density lipoprotein (HDL) and lowered very-low-density lipoprotein (VLDL). The mechanism by which PPARδ agonists increase HDL appears to be a result of increased expression of the cholesterol transporter ABCA1.